Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

BACKGROUND: The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate disease are not available. We assessed whether azithromycin is effective in reducing hospital admission in patients with mild...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Lancet Respir Med
Main Authors: Hinks, Timothy S C, Cureton, Lucy, Knight, Ruth, Wang, Ariel, Cane, Jennifer L, Barber, Vicki S, Black, Joanna, Dutton, Susan J, Melhorn, James, Jabeen, Maisha, Moss, Phil, Garlapati, Rajendar, Baron, Tanya, Johnson, Graham, Cantle, Fleur, Clarke, David, Elkhodair, Samer, Underwood, Jonathan, Lasserson, Daniel, Pavord, Ian D, Morgan, Sophie, Richards, Duncan
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier 2021
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270523/
https://ncbi.nlm.nih.gov/pubmed/34252378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(21)00263-0
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים